Equities analysts predict that Insys Therapeutics Inc (NASDAQ:INSY) will announce earnings per share of ($0.20) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Insys Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.29). Insys Therapeutics also posted earnings per share of ($0.20) in the same quarter last year. The business is expected to announce its next earnings results on Thursday, March 14th.

According to Zacks, analysts expect that Insys Therapeutics will report full year earnings of ($1.08) per share for the current fiscal year, with EPS estimates ranging from ($1.16) to ($1.00). For the next financial year, analysts anticipate that the company will post earnings of ($0.52) per share, with EPS estimates ranging from ($0.89) to ($0.15). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for Insys Therapeutics.

Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings results on Monday, November 5th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.30 million during the quarter, compared to analysts’ expectations of $24.05 million. Insys Therapeutics had a negative net margin of 128.88% and a negative return on equity of 266.60%. The company’s revenue for the quarter was down 40.4% on a year-over-year basis. During the same period in the prior year, the company posted ($2.30) EPS.

A number of research analysts have commented on INSY shares. Zacks Investment Research raised Insys Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, October 11th. Jefferies Financial Group reaffirmed a “buy” rating and set a $10.00 target price on shares of Insys Therapeutics in a report on Friday, August 10th. ValuEngine raised Insys Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 1st. Piper Jaffray Companies set a $4.00 target price on Insys Therapeutics and gave the stock a “sell” rating in a report on Saturday, August 11th. Finally, Royal Bank of Canada reaffirmed a “buy” rating and set a $9.00 target price on shares of Insys Therapeutics in a report on Thursday, August 9th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $7.67.

INSY traded up $0.11 on Wednesday, reaching $6.57. The company’s stock had a trading volume of 8,800 shares, compared to its average volume of 412,268. Insys Therapeutics has a 1 year low of $5.04 and a 1 year high of $14.00. The company has a market capitalization of $499.09 million, a P/E ratio of -13.41 and a beta of 1.67.

A number of large investors have recently added to or reduced their stakes in the business. Bridgeway Capital Management Inc. lifted its holdings in shares of Insys Therapeutics by 11.2% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 84,700 shares of the specialty pharmaceutical company’s stock worth $854,000 after purchasing an additional 8,500 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of Insys Therapeutics by 47.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 31,105 shares of the specialty pharmaceutical company’s stock worth $225,000 after purchasing an additional 10,001 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Insys Therapeutics in the 3rd quarter worth approximately $113,000. Creative Planning bought a new stake in shares of Insys Therapeutics in the 3rd quarter worth approximately $153,000. Finally, Tower Research Capital LLC TRC bought a new stake in shares of Insys Therapeutics in the 2nd quarter worth approximately $131,000. 18.45% of the stock is currently owned by institutional investors.

About Insys Therapeutics

Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.

Further Reading: Bear Market – How and Why They Occur

Get a free copy of the Zacks research report on Insys Therapeutics (INSY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.